You might want to bring a cup of black coffee to the pilot on your next flight. Results from a major study conducted by the National Sleep Foundation suggest airline pilots are some of the sleepiest transportation workers in the country, along with train operators.
Source: http://www.msnbc.msn.com/id/3036697/vp/46687066#46687066
proposition 8 ricky martin chauncey billups caucus results exton zsa zsa gabor red dawn
ATLANTA (Reuters) - Adults applying for welfare in Georgia would have to pass a drug test before receiving benefits under a bill approved by the state Senate late on Wednesday.
The legislation, called the Social Responsibility and Accountability Act, is designed to ensure that welfare payments, called Temporary Assistance to Needy Families, are "not diverted to illicit drug use."
The legislation, which now goes to the Georgia House, would not affect welfare payments to children. Under the bill, if a parent failed a drug test, children could still receive payments through another person designated by the state.
Two states, Michigan and Florida, have adopted similar legislation, according to the National Conference of State Legislatures. The Michigan Court of Appeals in 2003 ruled that state's law unconstitutional. Florida's law has been temporarily blocked by a federal lawsuit.
The American Civil Liberties Union of Georgia opposes the drug-testing requirement, the organization's executive director, Debbie Seagraves, told Reuters.
"Blanket drugs tests of any kind by the government are unconstitutional," she said.
Seagraves predicted Georgia would face a lengthy court fight over the legislation if it won final passage and is signed into law.
Republican State Senator John Albers, one of the sponsors of the bill, told Reuters he was confident the legislation would withstand any court challenges.
Welfare reform legislation passed by Congress in 1996 specifically allows states to require drug testing, he said. The Georgia bill is aimed at encouraging welfare recipients to stop using illegal drugs, Albers added.
"True compassion is doing what is best for people, not the easiest," he said.
(Editing by Tom Brown and Paul Thomasch)
Source: http://news.yahoo.com/georgia-senate-oks-drug-tests-welfare-applicants-171240825.html
nazi ss andrej pejic naomi watts macaulay culkin steve jobs fbi safehouse brown recluse
HOUSTON?As Congress slogged through a mishmash of mostly political messaging votes on energy and environmental policies, a top industry executive warned that America?s lack of an energy policy could compel global companies to invest elsewhere.
?We need a smart, prudent national framework and proactive energy policy that uses the collective wealth of this country,? Dow Chemical CEO and President Andrew Liveris said on Thursday at a major energy conference here. ?That?s hard to do in two-, four-, and six-year election cycles. But we have to do it.?
The Senate voted on Thursday on five disparate measures that affect different parts of the U.S. energy landscape. All the measures except one failed. The one successful vote was on bipartisan legislation requiring that 80 percent of the fines that oil giant BP pays in response to its 2010 spill go into restoration efforts in the Gulf of Mexico.? The measures that failed include proposals delaying mercury rules for industrial boilers, expanding offshore oil and gas drilling, and mandating approval of the controversial Keystone XL pipeline.
Liveris, who leads one of the world?s biggest chemical companies and is based in Michigan, said inaction on energy issues by the U.S. government will drive investments away.
?We will go to a country that will have a more robust and comprehensive energy policy,? he said during a speech to hundreds of the world?s top energy executives at the IHS Cambridge Energy Research Associates annual conference. ?Saudia Arabia understands that. China understands. Singapore understands that. Germany understands. Want me to keep going?? Liveris rhetorically asked. ?There have been 45 countries I?ve visited that understand. The United States understands but it has not been able to implement it.?
Source: http://news.yahoo.com/chemical-exec-warns-against-inaction-energy-policy-180523501.html
st. croix st. croix threadworm nick swisher pirates of silicon valley htc flyer tablet htc flyer tablet
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vcdl0oGMpH_NqzrzZqppHLA3RHhnGqW2I65boYTkg1nE0Q6TKlmXdx5GxgKa28UR1Z52aPbfnvAWlW5Iop10hoKlfF01WOndYO6f79w3Q=s0-d){kind=small}
Public release date: 8-Mar-2012
Share ] Contact: Jessa Netting
jnetting@ccny.cuny.edu
212-650-7615
City College of New York
The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.
The new designer aspirin curbed the growth of 11 different types of human cancer cells in culture without harming normal cells, reported a team from the Sophie Davis School of Biomedical Education of The City College of New York in a paper published this month in the journal ACS Medicinal Chemistry Letters. The cancers controlled included colon, pancreatic, lung, prostate, breast, and leukemia. "The key components of this new compound are that it is very, very potent and yet it has minimal toxicity to the cells," said Associate Professor Khosrow Kashfi, the principal investigator.
The aspirin compound also shrank human colon cancer tumors by 85 percent in live animals, again without adverse effects, according to a second paper in press by the City College researchers and colleague Kenneth Olson of Indiana University School of Medicine, South Bend. Their results will appear in the journal Biochemical and Biophysical Research Communications, now available online. "If what we have seen in animals can be translated to humans," said Professor Kashfi, "it could be used in conjunction with other drugs to shrink tumors before chemotherapy or surgery."
Long the go-to drug for minor aches and pains, aspirin and other so-called non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, are known primarily for their ability to calm inflammation. Studies in the 1980's resolved a decades-old debate on the utility of a daily dose of aspirin to cut the risk of heart attack and stroke.
More recent studies tracking regular use of the drug and other NSAIDs demonstrated their remarkable ability to inhibit the growth of cancer. "There's a lot of data on aspirin showing that when taken on a regular basis, on average it reduces the risk of development of colon cancer by about 50% compared to nonusers," noted Professor Kashfi.
The fly in the ointment has been that prolonged use of aspirin posed its own dangers: side effects ranging from bleeding ulcers to kidney failure. To resolve this, the researchers created a hybrid of two earlier formulations, which they have called "NOSH-aspirin." They used the aspirin as a scaffold to support two molecules that have been shown to increase the drug's safety and potency.
One arm of the hybrid aspirin releases nitric oxide (NO), which helps protect the stomach lining. The other releases hydrogen sulfide (H2S), which the researchers have previously shown enhances aspirin's cancer-fighting ability. The researchers suspected that the hybrid would be more effective than either of the two components alone to boost aspirin's safety and power against cancer.
"The hybrid is more potent and it is more potent by orders of magnitude compared to aspirin," said Kashfi. Only 24 hours after treating a culture of cancer cells, the NOSH-aspirin demonstrated 100,000 times greater potency than aspirin alone. "At 72 hours it is about 250,000 times more potent in an in-vitro cell culture against human colon cancer," Kashfi added. "So you need a lower amount to get the same result."
The effect of the hybrid was also far greater than the sum of its parts. Its potency was as much as 15,000 times greater than existing NO-aspirins and 80-fold more than those that incorporate H2S. The upshot is that a drug based on this hybrid would require lower doses to be effective, minimizing or potentially eliminating its side effects.
In the second study, when mice bearing human colon cancer tumors on their flanks were given oral NOSH-aspirin, the compound caused cancer cells to self-destruct, inhibited the proliferation of the cells and significantly reduced tumor growth without any signs of toxicity in the mice.
The stage is set for the development of a drug based on NOSH-aspirin. Kashfi noted that any working therapy for humans is years away, but the next step would be toxicity testing, and then clinical trials.
Dr. Ravinder Kodela and Dr. Mitali Chattopadhyay are members of Professor Kashfi's lab at Sophie Davis School of Biomedical Education and co-authors on both papers. These studies were funded by The National Cancer Institute through a subcontract from ThermoFisher, and also by the National Science Foundation.
Professor Kashfi and his colleagues will present these findings at the annual meeting of the American Association for Cancer Research in Chicago, March 31st - April 4th.
###
On the Internet:
Khoshrow Kashfi profile: http://www1.ccny.cuny.edu/prospective/med/faculty/kkashfi.cfm
References:
Ravinder Kodela, Mitali Chattopadhyay, and Khosrow Kashfi. NOSH-Aspirin: A Novel Nitric OxideHydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. Published online ACS Medicinal Chemistry Letters Article ASAP Publication Date (Published online ahead of print January 28, 2012) doi: 10.1021/ml300002m
http://pubs.acs.org/doi/abs/10.1021/ml300002m
M. Chattopadhyay et al., NOSHaspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model, Biochem. Biophys. Res. Commun. (In press. Available online February 2012), doi:10.1016/j.bbrc.2012.02.051
http://www.sciencedirect.com/science/article/pii/S0006291X12002847
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 8-Mar-2012 Share ] Contact: Jessa Netting
jnetting@ccny.cuny.edu
212-650-7615
City College of New York
The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.
The new designer aspirin curbed the growth of 11 different types of human cancer cells in culture without harming normal cells, reported a team from the Sophie Davis School of Biomedical Education of The City College of New York in a paper published this month in the journal ACS Medicinal Chemistry Letters. The cancers controlled included colon, pancreatic, lung, prostate, breast, and leukemia. "The key components of this new compound are that it is very, very potent and yet it has minimal toxicity to the cells," said Associate Professor Khosrow Kashfi, the principal investigator.
The aspirin compound also shrank human colon cancer tumors by 85 percent in live animals, again without adverse effects, according to a second paper in press by the City College researchers and colleague Kenneth Olson of Indiana University School of Medicine, South Bend. Their results will appear in the journal Biochemical and Biophysical Research Communications, now available online. "If what we have seen in animals can be translated to humans," said Professor Kashfi, "it could be used in conjunction with other drugs to shrink tumors before chemotherapy or surgery."
Long the go-to drug for minor aches and pains, aspirin and other so-called non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, are known primarily for their ability to calm inflammation. Studies in the 1980's resolved a decades-old debate on the utility of a daily dose of aspirin to cut the risk of heart attack and stroke.
More recent studies tracking regular use of the drug and other NSAIDs demonstrated their remarkable ability to inhibit the growth of cancer. "There's a lot of data on aspirin showing that when taken on a regular basis, on average it reduces the risk of development of colon cancer by about 50% compared to nonusers," noted Professor Kashfi.
The fly in the ointment has been that prolonged use of aspirin posed its own dangers: side effects ranging from bleeding ulcers to kidney failure. To resolve this, the researchers created a hybrid of two earlier formulations, which they have called "NOSH-aspirin." They used the aspirin as a scaffold to support two molecules that have been shown to increase the drug's safety and potency.
One arm of the hybrid aspirin releases nitric oxide (NO), which helps protect the stomach lining. The other releases hydrogen sulfide (H2S), which the researchers have previously shown enhances aspirin's cancer-fighting ability. The researchers suspected that the hybrid would be more effective than either of the two components alone to boost aspirin's safety and power against cancer.
"The hybrid is more potent and it is more potent by orders of magnitude compared to aspirin," said Kashfi. Only 24 hours after treating a culture of cancer cells, the NOSH-aspirin demonstrated 100,000 times greater potency than aspirin alone. "At 72 hours it is about 250,000 times more potent in an in-vitro cell culture against human colon cancer," Kashfi added. "So you need a lower amount to get the same result."
The effect of the hybrid was also far greater than the sum of its parts. Its potency was as much as 15,000 times greater than existing NO-aspirins and 80-fold more than those that incorporate H2S. The upshot is that a drug based on this hybrid would require lower doses to be effective, minimizing or potentially eliminating its side effects.
In the second study, when mice bearing human colon cancer tumors on their flanks were given oral NOSH-aspirin, the compound caused cancer cells to self-destruct, inhibited the proliferation of the cells and significantly reduced tumor growth without any signs of toxicity in the mice.
The stage is set for the development of a drug based on NOSH-aspirin. Kashfi noted that any working therapy for humans is years away, but the next step would be toxicity testing, and then clinical trials.
Dr. Ravinder Kodela and Dr. Mitali Chattopadhyay are members of Professor Kashfi's lab at Sophie Davis School of Biomedical Education and co-authors on both papers. These studies were funded by The National Cancer Institute through a subcontract from ThermoFisher, and also by the National Science Foundation.
Professor Kashfi and his colleagues will present these findings at the annual meeting of the American Association for Cancer Research in Chicago, March 31st - April 4th.
###
On the Internet:
Khoshrow Kashfi profile: http://www1.ccny.cuny.edu/prospective/med/faculty/kkashfi.cfm
References:
Ravinder Kodela, Mitali Chattopadhyay, and Khosrow Kashfi. NOSH-Aspirin: A Novel Nitric OxideHydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. Published online ACS Medicinal Chemistry Letters Article ASAP Publication Date (Published online ahead of print January 28, 2012) doi: 10.1021/ml300002m
http://pubs.acs.org/doi/abs/10.1021/ml300002m
M. Chattopadhyay et al., NOSHaspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model, Biochem. Biophys. Res. Commun. (In press. Available online February 2012), doi:10.1016/j.bbrc.2012.02.051
http://www.sciencedirect.com/science/article/pii/S0006291X12002847
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-03/ccon-can030812.php
juan williams victor martinez alcatraz scott walker recall cruise ship derek fisher martin luther king jr.
New Jersey Movers Camden New Jersey 08101
Camden NJ 08101
Arrange your utilities:
?NJ best moving source?.
Services Provide:
We have relocation trucks of every size and gather all insurance necessities, and are check for protection often to create surely that your property, furniture, antiques, and valuable property are kept safe in moving. Relocation Company One has years of knowledge relocation residential and business clients. Moving Company One offers an assortment of services include long distance residential relocating services or business relocating service. We are an recognized relocating services business; we give all type of trucks and gear for your move. We carry every type of trucks ranging from small to 48ft automobile with a tailgate, pull-out slope or air attack delay. If you are look for a reliable relocation service for your local moving want, out of state relocating, or business relocating, local Movers New Jersey is your fiest choice! Local Movers NJ has a mission to be amoungst the top moving firms. We act as a one point hub that will assist you when you desire to move to city, state or beyond. We supply skills and knowledge along with related resources to create your relocation price-effective, efficient, smooth, and superb! At local Mover NJ, you are supply} all relocate} {effectively all probable help that is needed for smooth relocation of your effective possessions with assist of an expert mover. We provide you assistance on defense to be taken before, through and after the relocating exercise. We can indeed help you to arrange your move effectively. General Movers is a full services certified and Insure Relocation Business services dedicated to give you with exceptional timely and resourceful service. We recognize that relocating takes huge total of time, power, and pressure and that is why it is key that you discover a relocation company that is on your side. Each relocating and every customer is powerfully individual; it has its possess exact requirements. We will listen to your needs, offer suggestion and supply you with useful relocating information.
Source: http://www.bestmoversusa.com/top-new-jersey-movers-camden-nj-08101/
ryan leaf ryan leaf jahvid best libya map libya map world series game 2
Self Improvement With Affirmations ? Affirmations are very powerful resources that can be essential in bringing about modify in your life, whether it is in the type of personal modify or bringing new conditions into your daily life. Self-affirmations are healing, optimistic messages that you give to by yourself to counter your unfavorable messages. Affirmations resemble visualization with mental pictures but words are used rather.
Video Rating: 4 / 5
Source: http://johnkrol.mobi/?p=10939
cher morgellons nhl all star draft touch nitrous oxide rihanna thug life tattoo chuck pagano
If you aren?t disgusted by The Cancer Prevention & Research Institute of Texas, you should be. They recently announced a new policy where universities without smoking bans would be denied cancer research funds. UNT received about $200,000 of funding from CPRIT last year for a study on prostate cancer. I think it?s time we gave the money back or at least severed ties with their organization.
Back in January, I received news that my father had prostate cancer. Prostate cancer isn?t the most popular cancer in terms of research funds. Compared to breast cancer, it kills roughly the same number of people while only receiving a third of the research funds. To see that CPRIT would deny UNT research funding because of its lack of smoking ban infuriated me. How do you tell people that you?re denying research funds because an institution respects individual liberties?
UNT needs to do the right thing and at the very least reject any funds from CPRIT. The policy is vague and draconian. It calls for ?a tobacco-free zone around each research building and all connected walkways and parking lots.? I understand that their goal is to eradicate cancer, but that goes too far. What is defined as a ?research building?? Even their PR specialist Ellen Price said, ?We don?t mind a complete ban.?
Yes, North Texas is trying to be a Tier One school, but we shouldn?t sacrifice individual liberty and bend over backwards to suit one institution. This policy is offensive, and to hold cancer funds hostage is absolutely unacceptable.
Where do the stipulations end?
Will CPRIT one day deny research funds because UNT serves red meat, or because we don?t require enough physical education hours or even because we don?t regulate the amount of sugar served in our cafeterias?
We cannot accept these terms as a university. Our 25-feet-from-the-building rule is more than OK, and if that can?t even be enforced then what?s to say that the ?tobacco-free zone? will be enforced either?
Yes, cancer is terrible, but so is the destruction of individual liberties. The students at this school oppose a total ban on smoking, why should we use this as a way of subverting their wishes?
Nicholas LaGrassa is an emergency administration and planning senior. He can be reached at NicholasLaGrassa@my.unt.edu.
Source: http://www.ntdaily.com/?p=63561
sun flare big ten tournament 2012 jessica sanchez sean hannity solar flare toyota recall new ipad
